Adult: As film-coated tab: 10 mg to be taken 2 hours prior to exercise; no additional doses to be taken within 24 hours. Child: 2-5 years As granules or chewable tab: 4 mg; 6-14 years As chewable tab: 5 mg; ≥15 years Same as adult dose. Doses to be taken 2 hours prior to exercise; no additional doses to be taken within 24 hours. Evaluate patient after 2-4 weeks of treatment.
Oral Allergic rhinitis
Adult: As film-coated tab: 10 mg once daily (taken in the evening for asthmatic patients; for nonasthmatic patient, doses may be taken either in the morning or evening). Child: ≥15 years Same as adult dose.
Oral Chronic asthma
Adult: As film-coated tab: 10 mg once daily in the evening. Child: 6 months-<2 years As granules: 4 mg once daily. 2-5 years As granules or chewable tab: 4 mg once daily; 6-14 years As chewable tab: 5 mg once daily; ≥15 years Same as adult dose. All doses to be taken in the evening. Evaluate patient after 2-4 weeks of treatment.
Aspirin-sensitive asthmatic patient must continue avoiding aspirin and other NSAIDs. Not intended for treatment of acute asthma attacks. Not recommended as monotherapy in treatment of moderate chronic asthma. Avoid abrupt substitution to oral or inhaled corticosteroids. Children. Pregnancy and lactation.
Decrease plasma concentration with CYP450 inducers (e.g. phenytoin, phenobarbital, rifampicin). Gemfibrozil may increase montelukast serum concentration.
Description: Montelukast is a selective leukotriene receptor antagonist with a long duration of action. It inhibits cysteinyl leukotriene type-1 (CysLT1) receptor found in the human airway and on pro-inflammatory cells. The binding of CysLTs in leukotriene receptors are involved in the pathophysiology of asthma, including smooth muscle contraction, airway oedema and inflammation; CysLTs are released from the nasal mucosa after allergen exposure which is associated with symptoms of allergic rhinitis. Onset: Asthma control: Within a day. Duration: >24 hours. Pharmacokinetics: Absorption: Rapidly absorbed. Bioavailability: 64% (conventional tab); 73% (chewable tab), 63% (with standard meal). Time to peak plasma concentration: 3-4 hours (conventional tab, fasting); 2 hours (4 mg chewable tab, fasting); 2-2.5 hours (5 mg chewable tab, fasting); 2.3±1 hour (granules, fasting), 6.4±2.9 hours (with high-fat meal). Distribution: Present in breastmilk. Volume of distribution: 8-11 L. Plasma protein binding: >99%. Metabolism: Extensively metabolised in the liver by CYP3A4, CYP2C8 and CYP2C9. Excretion: Mainly via faeces (86%); via urine (<0.2%). Elimination half-life: 2.7-5.5 hours.
Store below 30°C. Protect from light and moisture.
R03DC03 - montelukast ; Belongs to the class of leukotriene receptor antagonists. Used in the systemic treatment of obstructive airway diseases.
Anon. Montelukast. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 21/05/2019.Buckingham R (ed). Montelukast Sodium. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 21/05/2019.McEvoy GK, Snow EK, Miller J et al (eds). Montelukast Sodium. AHFS Drug Information (AHFS DI) [online]. American Society of Health-System Pharmacists (ASHP). https://www.medicinescomplete.com. Accessed 30/09/2014.Montelukast Granule, Tablet (Ajanta Pharma Limited). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 21/05/2019.Montelukast Tablet (Amneal Pharmaceuticals LLC). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 21/05/2019.Singulair Tablets, Chewable Tablets, and Oral Granules. U.S. FDA. https://www.fda.gov/. Accessed 30/09/2014.Singulair Granule, Chewable Tablet, Film-Coated Tablet (Merck Sharp & Dohme Corp.). DailyMed. Source: U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/. Accessed 30/09/2014.Singulair Granule. U.S. FDA. https://www.fda.gov/. Accessed 30/09/2014.